| Literature DB >> 33122481 |
Hazem Mansour1, Mona Rayan1, Mina Shnoda2, Diaa Kamal1.
Abstract
OBJECTIVE: Acute myocardial infarction (AMI) is the main cause of cardiovascular events worldwide. AMI commonly occurs in elderly patients because of atherosclerotic process related to common risk factors. Consequently, the rupture of atheromatous plaque with deleterious sequela is the common etiology of the disease. However, there are less studied etiological factors in youth compared with the usual population. Therefore, this study aimed to examine the risk profile of Egyptian youth presenting with AMI.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33122481 PMCID: PMC7724384 DOI: 10.14744/AnatolJCardiol.2020.67206
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Clinical profile and risk factors of the study group
| n=106 | |
|---|---|
| Age | |
| Mean±SD | 39.32±5.28 |
| Range | 24–55 |
| Sex | |
| Females | 5 (4.7%) |
| Males | 101 (95.3%) |
| BMI | |
| Mean±SD | 27.81±2.23 |
| Range | 23–33 |
| STEMI/NSTEMI | |
| NSTEMI | 35 (33.0%) |
| STEMI | 71 (67.0%) |
| Anterior/inferior | |
| Anterior | 49 (69.0%) |
| Inferior | 20 (28.2%) |
| Lateral | 2 (2.8%) |
| Smoking | |
| No | 13 (12.3%) |
| Yes | 93 (87.7%) |
| IV drug abuse | |
| Negative | 104 (98.1%) |
| Positive | 2 (1.9%) |
| Tramadol addiction | |
| Negative | 75 (70.8%) |
| Positive | 31 (29.2%) |
| Hash (cannabis) smoking | |
| Negative | 63 (59.4%) |
| Positive | 43 (40.6%) |
| Diabetes mellitus | |
| Negative | 84 (79.2%) |
| Positive | 22 (20.8%) |
| Hypertension | |
| Negative | 69 (65.1%) |
| Positive | 37 (34.9%) |
| LDL level | |
| Normal | 86 (81.1%) |
| High | 20 (18.9%) |
| HDL level | |
| Normal | 59 (55.7%) |
| Low | 47 (44.3%) |
| FH of premature CAD | |
| Negative | 86 (81.1%) |
| Positive | 20 (18.9%) |
| Peak CKMB | |
| Mean±SD | 242.32±194.37 |
| Range | 40–786 |
| LCX | |
| Negative | 88 (83.0%) |
| Positive | 18 (17.0%) |
| LAD | |
| Negative | 43 (40.6%) |
| Positive | 63 (59.4%) |
| RCA | |
| Negative | 79 (74.5%) |
| Positive | 27 (25.5%) |
| NSL | |
| Negative | 103 (97.2%) |
| Positive | 3 (2.8%) |
BMI - body mass index; STEMI - ST elevation myocardial infarction; NSTEMI - non-ST elevation myocardial infarction; LDL - low-density lipoprotein; HDL - high-density lipoprotein; FH - family history; CAD - coronary artery disease; LCX - left circumflex artery; LAD - left anterior descending artery; RCA - right coronary artery; NSL - non significant lesion
Relationship between AMI presentation and other parameters
| STEMI/NSTEMI | |||
|---|---|---|---|
| NSTEMI n=35 | STEMI n=71 | ||
| Age | |||
| Mean±SD | 40.77±4.21 | 38.61±5.62 | 0.046 |
| Range | 31–48 | 24–55 | |
| BMI | |||
| Mean±SD | 28.63±2.29 | 27.41±2.10 | 0.007 |
| Range | 23–33 | 23–32 | |
| Sex | |||
| Females | 4 (11.4%) | 1 (1.4%) | 0.022 |
| Males | 31 (88.6%) | 70 (98.6%) | |
| Smoking | |||
| No | 2 (5.7%) | 11 (15.5%) | 0.149 |
| Yes | 33 (94.3%) | 60 (84.5%) | |
| IV drug abuse | |||
| Negative | 34 (97.1%) | 70 (98.6%) | 0.606 |
| Positive | 1 (2.9%) | 1 (1.4%) | |
| Tramadol addiction | |||
| Negative | 29 (82.9%) | 46 (64.8%) | 0.054 |
| Positive | 6 (17.1%) | 25 (35.2%) | |
| Hash smoking | |||
| Negative | 27 (77.1%) | 36 (50.7%) | 0.009 |
| Positive | 8 (22.9%) | 35 (49.3%) | |
| Diabetes mellitus | |||
| Negative | 20 (57.1%) | 64 (90.1%) | <0.001 |
| Positive | 15 (42.9%) | 7 (9.9%) | |
| Hypertension | |||
| Negative | 13 (37.1%) | 56 (78.9%) | <0.001 |
| Positive | 22 (62.9%) | 15 (21.1%) | |
| LDL level | |||
| Normal | 20 (57.1%) | 66 (93.0%) | <0.001 |
| High | 15 (42.9%) | 5 (7.0%) | |
| HDL level | |||
| Normal | 17 (48.6%) | 42 (59.2%) | 0.302 |
| Low | 18 (51.4%) | 29 (40.8%) | |
| FH of premature CAD | |||
| Negative | 24 (68.6%) | 62 (87.3%) | 0.020 |
| Positive | 11 (31.4%) | 9 (12.7%) | |
P>0.05, not significant; P<0.05, significant; P<0.01, highly significant. BMI - body mass index; STEMI - ST elevation myocardial infarction; NSTEMI - non-ST elevation myocardial infarction; LDL - low-density lipoprotein; HDL - high-density lipoprotein; FH - family history; CAD - coronary artery disease
Univariate and multiple logistic regression analyses for factors related to AMI presentation
| Univariate | Multiple | |||
|---|---|---|---|---|
| P | OR (95% CI) | P | OR (95% CI) | |
| Age | 0.052 | 0.917 (0.840–1.001) | - | - |
| BMI | 0.010 | 0.766 (0.625–0.938) | 0.925 | 1.016 (0.725-1.425) |
| Sex | 0.053 | 9.032 (0.970–84.144) | - | - |
| Hash smoking (cannabis) | 0.011 | 3.281 (1.313–8.200) | 0.289 | 2.600 (0.444–15.214) |
| Diabetes mellitus | <0.001 | 0.146 (0.052–0.408) | 0.765 | 0.724 (0.088–5.993) |
| Hypertension | <0.001 | 0.158 (0.065–0.386) | 0.098 | 0.198 (0.029–1.349) |
| LDL level | <0.001 | 0.101 (0.033–0.312) | 0.165 | 0.278 (0.046–1.695) |
| FH of premature CAD | 0.024 | 0.317 (0.117–0.860) | 0.197 | 0.262 (0.034–2.009) |
BMI - body mass index; OR - odds ratio; CI - confidence interval; LDL - low-density lipoprotein; FH - family history; CAD - coronary artery disease
Relationship between LAD involvement and other parameters
| LAD | |||
|---|---|---|---|
| Negative n=43 | Positive n=63 | ||
| Age | |||
| Mean±SD | 39.49±5.17 | 39.21±5.38 | 0.788 |
| Range | 24–55 | 27–45 | |
| Sex | |||
| Females | 1 (2.3%) | 4 (6.3%) | 0.337 |
| Males | 42 (97.7%) | 59 (93.7%) | |
| BMI | |||
| Mean±SD | 28.05±1.90 | 27.65±2.43 | 0.372 |
| Range | 23–32 | 23–33 | |
| Smoking | |||
| No | 2 (4.7%) | 11 (17.5%) | 0.050 |
| Yes | 41 (95.3%) | 52 (82.5%) | |
| IV drug abuse | |||
| Negative | 42 (97.7%) | 62 (98.4%) | 0.784 |
| Positive | 1 (2.3%) | 1 (1.6%) | |
| Tramadol addiction | |||
| Negative | 36 (83.7%) | 39 (61.9%) | 0.015 |
| Positive | 7 (16.3%) | 24 (38.1%) | |
| Hash smoking | |||
| Negative | 25 (58.1%) | 38 (60.3%) | 0.823 |
| Positive | 18 (41.9%) | 25 (39.7%) | |
| Stress level | |||
| Normal | 1 (2.3%) | 3 (4.8%) | 0.659 |
| Low | 3 (7.0%) | 7 (11.1%) | |
| Moderate | 25 (58.1%) | 38 (60.3%) | |
| High | 14 (32.6%) | 15 (23.8%) | |
| Diabetes mellitus | |||
| Negative | 31 (72.1%) | 53 (84.1%) | 0.134 |
| Positive | 12 (27.9%) | 10 (15.9%) | |
| Hypertension | |||
| Negative | 22 (51.2%) | 47 (74.6%) | 0.013 |
| Positive | 21 (48.8%) | 16 (25.4%) | |
| Peak CKMB | |||
| Mean±SD | 194.74±158.79 | 274.79±210.38 | 0.037 |
| Range | 45–786 | 40–755 | |
| LDL level | |||
| Normal | 34 (79.1%) | 52 (82.5%) | 0.654 |
| High | 9 (20.9%) | 11 (17.5%) | |
| HDL level | |||
| Normal | 28 (65.1%) | 31 (49.2%) | 0.105 |
| Low | 15 (34.9%) | 32 (50.8%) | |
| FH of premature CAD | |||
| Negative | 34 (79.1%) | 52 (82.5%) | 0.654 |
| Positive | 9 (20.9%) | 11 (17.5%) | |
P>0.05, not significant; P<0.05, significant; P<0.01, highly significant. BMI - body mass index; STEMI - ST elevation myocardial infarction; NSTEMI - non-ST elevation myocardial infarction; LDL - low-density lipoprotein; HDL - high-density lipoprotein; FH - family history; CAD - coronary artery disease; CK-MB: Creatine kinase-MB
Univariate and multiple logistic regression analyses related to LAD involvement
| Univariate | Multiple | |||||||
|---|---|---|---|---|---|---|---|---|
| OR | Lower | Upper | OR | Lower | Upper | |||
| Tramadol addiction | 0.018 | 3.165 | 1.217 | 8.233 | 0.032 | 3.004 | 1.101 | 8.195 |
| Hypertension | 0.014 | 0.357 | 0.156 | 0.813 | 0.103 | 0.459 | 0.180 | 1.169 |
| Peak CKMB | 0.042 | 1.002 | 1.000 | 1.005 | 0.374 | 1.001 | 0.999 | 1.004 |
OR - odds ratio; CK-MB: Creatine kinase-MB
Association between illicit drug use and presence of heavy thrombus
| Heavy thrombus burden | ||||
|---|---|---|---|---|
| Negative | Positive | |||
| Tramadol addiction | Negative | 50 (66.7%) | 10 (32.3%) | 0.001 |
| Positive | 25 (33.3%) | 21 (67.7%) | ||
| Hash (cannabis) smoking | Negative | 43 (68.3%) | 17 (39.5%) | 0.003 |
| Positive | 20 (31.7%) | 26 (60.5%) | ||
Relationship between tramadol addiction and other parameters
| Tramadol addiction | |||
|---|---|---|---|
| Negative n=75 | Positive n=31 | ||
| Age | |||
| Mean±SD | 39.12±5.58 | 39.81±4.50 | 0.545 |
| Range | 24–55 | 27–48 | |
| Sex | |||
| Females | 5 (6.7%) | 0 (0.0%) | 0.141 |
| Males | 70 (93.3%) | 31 (100.0%) | |
| STEMI/NSTEMI | |||
| NSTEMI | 29 (38.7%) | 6 (19.4%) | 0.054 |
| STEMI | 46 (61.3%) | 25 (80.6%) | |
| Anterior/Inferior | |||
| Anterior | 27 (58.7%) | 22 (88.0%) | 0.035 |
| Inferior | 17 (37.0%) | 3 (12.0%) | |
| Lateral | 2 (4.3%) | 0 (0.0%) | |
| Smoking | |||
| No | 13 (17.3%) | 0 (0.0%) | 0.013 |
| Yes | 62 (82.7%) | 31 (100.0%) | |
| Range | 6–30 | 10–30 | |
| IV drug abuse | |||
| Negative | 73 (97.3%) | 31 (100.0%) | 0.359 |
| Positive | 2 (2.7%) | 0 (0.0%) | |
| Hash (cannabis) smoking | |||
| Negative | 50 (66.7%) | 13 (41.9%) | 0.018 |
| Positive | 25 (33.3%) | 18 (58.1%) | |
| Diabetes mellitus | |||
| Negative | 62 (82.7%) | 22 (71.0%) | 0.177 |
| Positive | 13 (17.3%) | 9 (29.0%) | |
| Hypertension | |||
| Negative | 48 (64.0%) | 21 (67.7%) | 0.713 |
| Positive | 27 (36.0%) | 10 (32.3%) | |
| LDL level | |||
| Normal | 59 (78.7%) | 27 (87.1%) | 0.313 |
| High | 16 (21.3%) | 4 (12.9%) | |
| HDL level | |||
| Normal | 43 (57.3%) | 16 (51.6%) | 0.590 |
| Low | 32 (42.7%) | 15 (48.4%) | |
| Peak CKMB | |||
| Mean±SD | 231.65±189.25 | 268.13±207.16 | 0.382 |
| Range | 40–786 | 40–710 | |
| LCX | |||
| Negative | 58 (77.3%) | 30 (96.8%) | 0.015 |
| Positive | 17 (22.7%) | 1 (3.2%) | |
| LAD | |||
| Negative | 36 (48.0%) | 7 (22.6%) | 0.015 |
| Positive | 39 (52.0%) | 24 (77.4%) | |
| RCA | |||
| Negative | 52 (69.3%) | 27 (87.1%) | 0.056 |
| Positive | 23 (30.7%) | 4 (12.9%) | |
| NSL | |||
| Negative | 74 (98.7%) | 29 (93.5%) | 0.148 |
| Positive | 1 (1.3%) | 2 (6.5%) | |
P>0.05, not significant; P<0.05, significant; P<0.01, highly significant. STEMI - ST elevation myocardial infarction; NSTEMI - non-ST elevation myocardial infarction; LDL - low-density lipoprotein; HDL - high-density lipoprotein; FH - family history; CAD - coronary artery disease; LCX - left circumflex artery; LAD - left anterior descending artery; RCA - right coronary artery; NSL - non significant lesion
Figure 1Association between hash (cannabis) smoking and CKMB
Figure 2Molecular mechanisms of interplay between cannabinoid system and platelets [Goyal et al., 2017 (5)]